Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod-induced murine psoriasis and impedes the trans-endothelial migration of mononuclear cells

Ernesto A. Vázquez-Sánchez, José S. Mendoza-Figueroa, Guadalupe Gutiérrez-Gonzalez, Luis A. Zapi-Colín, Azael Torales-Cardeña, Paola E. Briseño-Lugo, Iván Díaz-Toalá, Juan C. Cancino-Diaz, Sonia M. Pérez-Tapia, Mario E. Cancino-Diaz, Fernando Gómez-Chávez, Sandra Rodríguez-Martínez

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

2 Citas (Scopus)

Resumen

during the progression of psoriatic lesions, abundant cellular infiltration of myeloid cells, such as macrophages and activated dendritic cells, occurs in the skin and the infiltrating cells interact with naive lymphoid cells to generate a T helper (Th)1 and Th17 environment. Therapies to treat psoriasis include phototherapy, non-steroidal and steroidal drugs, as well as antibodies to block tumor necrosis factor-α, interleukin (il)-17-a and il-12/il-23, which all focus on decreasing the proinflammatory hallmark of psoriasis. The present study obtained the heptapeptide HP3 derived from phage display technology that blocks mononuclear cell adhesion to endothelial cells and inhibits trans-endothelial migration in vitro. The activity of the heptapeptide in a murine model of psoriasis was also assessed, which indicated that early administration inhibited the development of psoriatic lesions. Therefore, the results suggested that HP3 may serve as a potential therapeutic target for psoriasis.

Idioma originalInglés
Páginas (desde-hasta)507-515
Número de páginas9
PublicaciónMolecular Medicine Reports
Volumen22
N.º1
DOI
EstadoPublicada - jul. 2020

Huella

Profundice en los temas de investigación de 'Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod-induced murine psoriasis and impedes the trans-endothelial migration of mononuclear cells'. En conjunto forman una huella única.

Citar esto